Held virtually via zoom: Noon - 1 p.m. (CST)
Zoom Link
Meeting ID: 387 923 767
Passcode: 831342
| Date | Speaker | Title/Presentation |
|---|---|---|
| Aug. 23, 2021 | Lucy A. Godley, M.D., Ph.D. Hospira Foundation Professor of Medicine and Human Genetics University of Chicago Medicine |
Germline predisposition for myelodysplasia and acute myelogenous leukemia View Presentation (BCM login required) |
| Sept. 20, 2021 |
Ann Mullally, M.D. |
Towards Rationally Designed Approaches to Treat Pre-clinical and Overt MPN View Presentation (BCM login required) |
| Oct. 4, 2021 |
Ola Landgren, M.D., Ph.D. |
Advances in therapy of relapsed/refractory myeloma View Presentation (BCM login required) |
| Oct. 18, 2021 |
Justin Lathia, Ph.D. |
Cancer stem cell-immune system interactions drive disease progression |
| Nov. 1, 2021 |
Robert Kridel, M.D., M.P.H., Ph.D. |
Off the shelf CAR T Cells in B Cell Malignancies View Presentation (BCM login required) |
| Nov. 15, 2021 |
Charlotte Graham, Ph.D. |
Off the shelf CAR T Cells in B Cell Malignancies View Presentation (BCM login required) |
| Nov. 29, 2021 |
Enrico Derenzini, M.D., Ph.D. |
Exploring the DNA damage response as a therapeutic target in DLBCL? View Presentation (BCM login required) |
| Dec. 13, 2021 |
Navdeep S. Chandel, Ph.D. |
Unraveling Cancer cell Metabolism View Presentation (BCM login required) |
| Dec. 27, 2021 | Michael R. Bishop, M.D. University of Chicago |
Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphoma View Presentation (BCM login required) |
| Jan. 10, 2022 |
Eirini Papapetrou, M.D., Ph.D. |
Identifying novel AML targets View Presentation (BCM login required) |
| Jan. 24, 2022 |
Philippe Moreau, M.D. |
Myeloma International Working Group recommendations for treatment of relapsed and refractory disease |
| Feb. 7, 2022 |
Siddhartha Jaiswal, M.D., Ph.D. |
Clonal Hematopoiesis in Human Aging and Disease View Presentation (BCM login required) |
| Feb. 21, 2022 |
Matteo della Porta, M.D. |
Genomic of myelodysplastic syndrome |
| March 7, 2022 | Christopher Hourigan, M.D., D.Phil National Institutes of Health |
Advances in AML Measurable residual disease This presentation will not be recorded. |
| March 21, 2022 | Alexander Hollein Rotkreuzklinikum Münche, Munich Leukemia Laboratory, Munich Germany |
CHIP vs CHOP initiating mutations in myeloid malignant disorders View Presentation (BCM login required) |
| April 4, 2022 | Raheleh Rahbari, Cancer Research UK Career Development Fellow Sanger Wellcome Institute, London, UK |
Mutational landscape of somatic and germline mutations |
| April 18, 2022 | Ana Domestegui, Postdoctoral Fellow Institute of Biomedical Research, Barcelona, Spain |
Ribosomal activation and Myc-driven lymphoma lethality |
| May 2, 2022 | Narish Kikkeri Fred Hutchinson Research Cancer Center |
Revisiting recognition and enumeration of blasts in diagnosis and classification of myeloid neoplasm |
| May 16, 2022 | Jean-Emmanuel Sarry Centre de Recherches en Cancérologie de Toulouse |
Mitochondrial inhibitors to overcome venetoclax and cytarabine resistance in AML |
| June 6, 2022 | Naseema Gangat Mayo Clinic Rochester |
Primary refractory acute myeloid leukemia View Presentation (BCM login required) |
| July 11, 2022 | Jorge Castillo, M.D. Bing Center for Waldenstrom’s Macroglobulinemia Division of Hematological Malignancies, Dana-Farber CanceInstitute Harvard Medical School |
Management of Waldenstrom’s Macroglobulinemia in the Era of Targeted Therapies |
|
July 25, 2022 |
Daniel Starczynowski, Ph.D. |
TRAF6 as a novel tumor suppressor in myeloid malignancies |
| Aug. 8, 2022 | Ann-Kathrin Eisfeld, M.D. The Ohio State University |
Racial disparity and differential outcome in AML View Presentation (BCM login required) |
| Sept. 12, 2022 | Mikkael Sekeres, M.D., M.S., Chief of Hematology University of Miami Hospital and Clinical |
High-Risk Myelodysplastic Syndrome View Presentation (BCM login required) |
| Sept. 26, 2022 | Dr. Karen H Miga, Ph.D., University of California Santa Cruz | Discovering New Biology and Function in Complete, Telomere-to Telomere (T2T) Genomes |
